Financings

Lucence attracts $20M in series A to scale up operations

November 26, 2019

HONG KONG – Lucence Diagnostics Pte Ltd., a genomic medicine company headquartered in Singapore, has secured $20 million in series A investment.

Financings for Nov. 26, 2019

November 26, 2019

No Comments

Biopharmas in Asia-Pacific raising money in public or private financings.

Tot Biopharm raises $61M on HKEX, co-develops antibody with Harbour

November 12, 2019

By Elise Mak

No Comments

BEIJING – Chinese clinical-stage cancer drug developer Tot Biopharm International Co. Ltd. went public on Hong Kong's stock exchange under the stock code of 1875 on Friday, raising HK$511.4 million (US$61.3 million) by issuing shares at HK$6.55 apiece. But its debut met with an unexpected setback, with share prices down nearly 7% in mid-morning. Prior to the listing, the company said its shares were oversubscribed by around 11.95 times and it "was well received by the capital market."

Akeso closes $150M series D to advance first-in-class bispecific antibodies

November 7, 2019

By Elise Mak

No Comments

BEIJING – Antibody developer Akeso Biopharma Inc., from China's Guangdong province, closed a $150 million series D financing round to advance its pipeline, especially the two PD-1-based bispecific antibodies, AK-104 and AK-112, aimed to help it stand out in the fierce PD-1 space in China. "A significant portion of the proceeds will go to AK-104 and AK-112, which are both first-in-class drug candidates," Akeso CEO Michelle Xia told BioWorld. This year is a big one for Akeso, as AK-104 and AK-112 received IND approvals from the FDA in March and July, respectively.

AusBiotech 2019

Aussie immunology startup Kira Biotech launches with AU$20M series A financing

November 6, 2019

By Tamra Sami

No Comments

Brisbane-based Kira Biotech Pty Ltd. is poised to enter the clinic after raising AU$20 million (US$13.72 million) in series A funding to develop therapies targeting immune system disorders. The round was led by Oneventures, one of Australia's leading venture capital firms with more than AU$330 million in funds under management.

Financings for Nov. 6, 2019

November 6, 2019

No Comments

Biopharmas raising money in public or private financings.

Denovo launches pre-IPO financing to support phase III testing of DB-102 in DLBCL

November 6, 2019

By Elise Mak

No Comments

BEIJING – Cross-border biotech Denovo Biopharma LLC, registered in San Diego and Hangzhou, China, is planning for a pre-revenue listing on Shanghai's high-tech board (STAR) to support a key trial.

Financings for Oct. 28, 2019

October 28, 2019

No Comments

Biopharmas raising money in public or private financings.

Newco News

Korea's Genome & Co. adds $25.2M in series C financing

October 23, 2019

By Jihyun Kim

No Comments

HONG KONG – South Korea's biopharmaceutical venture Genome & Co. Ltd. recently secured KRW30.2 billion (US$25.2 million) in series C investment with an IPO and global clinical trial plans for next year.

U.K. asset manager Upin pledges $1.7B over 3 years to Korean biopharma sector

October 16, 2019

By Jihyun Kim

No Comments

HONG KONG – Upin & Co. Ltd., a fund and asset management company headquartered in London, plans to invest a total of KRW2 trillion (US$1.7 billion) over three years in the South Korean biopharma industry.